These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 31514546)

  • 21. Comparison between sodium cromoglycate (MDI: metered-dose inhaler) and beclomethasone dipropionate (MDI) in treatment of adult patients with mild to moderate bronchial asthma. A double-blind, double-dummy randomized, parallel-group study.
    Faurschou P; Bing J; Edman G; Engel AM
    Allergy; 1994 Sep; 49(8):659-63. PubMed ID: 7653745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial.
    Yoo SH; Park SH; Song JS; Kang KH; Park CS; Yoo JH; Choi BW; Hahn MH;
    Respirology; 2001 Mar; 6(1):15-21. PubMed ID: 11264758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A controlled trial of twice daily triamcinolone oral inhaler in patients with mild-to-moderate asthma.
    Ramsdell JW; Fish L; Graft D; Higgins N; Kavuru M; Pleskow W; Banerji D
    Ann Allergy Asthma Immunol; 1998 May; 80(5):385-90. PubMed ID: 9609607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma.
    Chan R; Sousa AR; Mallett S; Hynds P; Homayoun-Valiani F; Tabberer M; Mehta R
    Pulm Pharmacol Ther; 2016 Dec; 41():19-24. PubMed ID: 27599598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A placebo-controlled trial of procaterol: a new long-acting oral beta 2-agonist in bronchial asthma.
    Siegel SC; Katz RM; Rachelefsky GS; Brandon ML; Borgen LA
    J Allergy Clin Immunol; 1985 Jun; 75(6):698-705. PubMed ID: 2861219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of procaterol combined with inhaled budesonide for treatment of cough-variant asthma.
    Bao W; Chen Q; Lin Y; Liu H; Zhao G; Chen Z; Zhou X
    Respirology; 2013 Nov; 18 Suppl 3():53-61. PubMed ID: 24188204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of salmeterol/fluticasone propionate versus fluticasone propionate in asthma patients: a randomized, double-blind study.
    Lee YS; Lin HC; Huang CD; Lee KY; Liu CY; Yu CT; Wang CH; Kuo HP
    Chang Gung Med J; 2011; 34(4):382-94. PubMed ID: 21880193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial.
    Balki A; Balamurugan S; Bardapurkar S; Dalal S; Singh A; Singh BP; Vaidya A; Gogtay JA
    Pulm Pharmacol Ther; 2018 Feb; 48():28-36. PubMed ID: 28890299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group.
    Spector SL; Smith LJ; Glass M
    Am J Respir Crit Care Med; 1994 Sep; 150(3):618-23. PubMed ID: 8087328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.
    O'Byrne PM; D'Urzo T; Beck E; Fležar M; Gahlemann M; Hart L; Blahova Z; Toorawa R; Beeh KM
    Respir Res; 2015 Aug; 16(1):97. PubMed ID: 26283085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators.
    van der Molen T; Postma DS; Turner MO; Jong BM; Malo JL; Chapman K; Grossman R; de Graaff CS; Riemersma RA; Sears MR
    Thorax; 1997 Jun; 52(6):535-9. PubMed ID: 9227720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in pulmonary function and cross-sectional area of trachea and bronchi in asthmatics following inhalation of procaterol hydrochloride and ipratropium bromide.
    Hoffstein V; Zamel N; McClean P; Chapman KR
    Am J Respir Crit Care Med; 1994 Jan; 149(1):81-5. PubMed ID: 8111604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial.
    Płoszczuk A; Bosheva M; Spooner K; McIver T; Dissanayake S
    Ther Adv Respir Dis; 2018; 12():1753466618777924. PubMed ID: 29857783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma.
    D'Alonzo GE; Nathan RA; Henochowicz S; Morris RJ; Ratner P; Rennard SI
    JAMA; 1994 May; 271(18):1412-6. PubMed ID: 7909853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized equivalence trial: A novel multidose dry powder inhaler and originator device in adult and adolescent asthma.
    Kuna P; Thyroff-Friesinger U; Gath I; Jones S
    Allergy Asthma Proc; 2015; 36(5):352-64. PubMed ID: 26219538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.